Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 9/20 | 0.51 |
| ▸ | JAK2 | O60674 | 2/20 | 0.50 |
| ▸ | ROS1 | P08922 | 1/20 | 0.49 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.49 |
| ▸ | BRD4 | O60885 | 1/20 | 0.47 |
| ▸ | JAK3 | P52333 | 2/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | FLT3 | P36888 | 1/20 | 0.46 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5416251 | 0.90 | LRRK2 (0.60) | LRRK2JAK2ROS1ALK | |
| SCHEMBL5405428 | 0.89 | LRRK2 (0.47) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5410579 | 0.89 | LRRK2 (0.57) | LRRK2JAK2ROS1ALKJAK3 | |
| SCHEMBL5407979 | 0.87 | STK17A (0.46) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5414022 | 0.83 | LRRK2 (0.47) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5408196 | 0.81 | MEN1 (0.54) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5410626 | 0.80 | MEN1 (0.56) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5409983 | 0.80 | MEN1 (0.56) | LRRK2JAK2ROS1ALKBRD4 | |
| SCHEMBL5411594 | 0.79 | BRD4 (0.58) | LRRK2JAK2ALKBRD4NTRK1 | |
| SCHEMBL5405536 | 0.79 | ALK (0.54) | LRRK2JAK2ALKBRD4EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | LRRK2 619/4885JAK2 4450/4885ROS1 2088/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | LRRK2 775/4885JAK2 4231/4885ROS1 2422/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.